The reiteration of an Overweight rating by a reputable analyst like Louise Chen from Cantor Fitzgerald is a positive signal for Aravive. It suggests that the analyst believes the company's stock will outperform the market, which could lead to an increase in its stock price. The maintained price target of $18 also indicates that the analyst sees potential for the stock's price to rise.